Clinical Trials
31
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)โข Click on a phase to view related trials
Continuation Study for Latozinemab
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06111014
- Locations
- ๐บ๐ธ
Dignity Health - Arizona, Phoenix, Arizona, United States
๐บ๐ธMayo Comprehensive Cancer Center - PPDS, Rochester, Minnesota, United States
๐บ๐ธIrving Institute for Clinical and Translational Research, New York, New York, United States
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT05744401
- Locations
- ๐บ๐ธ
Banner Alzheimer's Institute, Phoenix, Arizona, United States
๐บ๐ธGeorgetown University Medical Center, Washington, District of Columbia, United States
๐บ๐ธSFM Clinical Research, LLC, Boca Raton, Florida, United States
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05053035
- Locations
- ๐บ๐ธ
University of South Florida, Tampa, Florida, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04592874
- Locations
- ๐บ๐ธ
Banner Alzheimer's Institute, Phoenix, Arizona, United States
๐บ๐ธWoodlands Research Network, LLC - ERG, Rogers, Arkansas, United States
๐บ๐ธATP Clinical Research, Costa Mesa, California, United States
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
- Conditions
- Frontotemporal Dementia
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04374136
- Locations
- ๐บ๐ธ
Dignity Health, Phoenix, Arizona, United States
๐บ๐ธUniversity of California San Diego, La Jolla, California, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next